The molecular pathogenesis of HCC is very complex and involves different pathways and molecular aberrations such as RAS/RAF/MEK/ERK, PI3K/AKT/mTOR, VEGF, c-Met, and HDACs, simultaneous or sequential elimination of the function of these key pathways or key molecules may improve the therapeutic dilemma of HCC patients. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.